Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart T-Cell engager aims to outsmart tumors in first human test

NCT ID NCT07702955

Not yet recruiting Disease control Sponsor: Kangabio AUSTRALIA LTD PTY Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 22, 2026 · Updated 3 times

Summary

This early-phase trial tests an experimental drug, KGX105, in people with advanced solid tumors that have not responded to standard treatments. KGX105 is designed to activate immune T-cells specifically within the tumor, potentially reducing side effects. The study will assess safety, dosing, and whether the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental prodrug called KGX105 that activates T-cells to attack tumors
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early, first-in-human trial with a small number of participants, so safety and effectiveness are not yet established. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal squamous cell carcinoma gastric cancer gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma malignant pancreatic neoplasm metastatic malignant neoplasm nasopharyngeal carcinoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED OR METASTATIC SOLID TUMORS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, 510060, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.